Green-top Guideline no. 74 Antenatal corticosteroids to reduce neonatal morbidity and mortality

The aim of this guideline is to provide evidence-based recommendations on the use of antenatal corticosteroids in women at risk of preterm birth or undergoing caesarean birth at term. 1: Key Recommendations (00:50) 2: Background and Scope (03:46 ) 3: Identification and Assessment of Evidence (06:27) 4: The Benefits of Antenatal Corticosteroids (07:30) 4.1: What are the benefits of corticosteroids in preterm labour and birth (07:35) 4.2 What are the benefits of corticosteroids in planned caesarean birth at term (10:04) Table 1: Risks and benefits of antenatal corticosteroids to be discussed and offered (16:46) 5: At what gestation should antenatal corticosteroids be discussed and offered (27:03) 6: In what particular circumstances would antenatal corticosteroids be discussed with and offered to women? (34:43) 6.1: Multiple pregnancy (34:54) 6.2 Women with diabetes mellitus (39:03) 6.3 Pregnancies complicated by fetal growth restriction, pre-eclampsia or antepartum haemorrhage (43:11) 6.4. Preterm, prelabour rupture of membranes (PPROM) (51:17) 7: What is the optimum dose and route of administration for a course of antenatal corticosteroids? (55:46) Betamethasone (58:44 ) Dexamethasone (1:01:00) 8: How long after administration is a course of antenatal corticosteroids most effective? (1:05:40) 9: What are the risks associated with the administration of antenatal corticosteroids? (1:17:50) 9.1: What are the risks to the woman? (1:19:00) 9.2: What are the risks to the baby? (1:20:53) 10 - What are the contraindications to the use of antenatal corticosteroids? (1:31:44 ) 11 - In what circumstances should an antenatal course of corticosteroids be repeated? (1:33:31) 12. Recommendations for future research (1:37:21) 13. Auditable topics (1:38:37) Closing Statement (1:39:52)